Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC

Condition:   Hepatocellular Carcinoma Interventions:   Drug: Sorafenib;   Procedure: Transarterial chemoembolization Sponsor:   Sun Yat-sen University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials